Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jan 6:33:27-29.
doi: 10.1016/j.jdcr.2023.01.001. eCollection 2023 Mar.

Dupilumab-induced pityriasis rosea

Morgan Zabel  1 , Grace A Hile  2 , Alanna Shefler  2 , Paul W Harms  2   3 , May P Chan  2   3 , Jennifer B Mancuso  2   4
Affiliations
Case Reports

Dupilumab-induced pityriasis rosea

Morgan Zabel et al. JAAD Case Rep. .
No abstract available

Keywords: IL, interleukin; cutaneous adverse reaction; dupilumab; medical dermatology; pityriasis rosea.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Clinical presentation. Multiple oval-to-round erythematous plaques with peripheral collarette of scale and central clearance.
Fig 2
Fig 2
Punch biopsy from the left flank. Mild acanthosis and spongiosis with mounded parakeratosis and perivascular lymphohistiocytic inflammation with scattered eosinophils (hematoxylin and eosin, 100×, inset highlighting eosinophils).
See this image and copyright information in PMC

References

    1. Harb H., Chatila T.A. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5–14. doi: 10.1111/cea.13491. - DOI - PMC - PubMed
    1. Muzumdar S., Skudalski L., Sharp K., Waldman R.A. Dupilumab facial redness/dupilumab facial dermatitis: a guide for clinicians. Am J Clin Dermatol. 2022;23(1):61–67. doi: 10.1007/s40257-021-00646-z. - DOI - PubMed
    1. Napolitano M., Scalvenzi M., Fabbrocini G., Cinelli E., Patruno C. Occurrence of psoriasiform eruption during dupilumab therapy for adult atopic dermatitis: a case series. Dermatol Ther. 2019;32 doi: 10.1111/dth.13142. - DOI - PubMed
    1. Shirley M. Dupilumab: first global approval. Drugs. 2017;77(10):1115–1121. doi: 10.1007/s40265-017-0768-3. - DOI - PubMed
    1. Parker J.J., Sugarman J.L., Silverberg N.B., et al. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children. Pediatr Dermatol. 2021;38(6):1500–1505. doi: 10.1111/pde.14820. - DOI - PubMed

Publication types

LinkOut - more resources